Bufalin reverses oxaliplatin resistance in gastric cancer by targeting YBX1 to suppress glycolysis.
Oxaliplatin resistance is a key challenge in gastric cancer therapy.
APA
Li X, Li Q, et al. (2026). Bufalin reverses oxaliplatin resistance in gastric cancer by targeting YBX1 to suppress glycolysis.. Biochemical pharmacology, 250(Pt 1), 117976. https://doi.org/10.1016/j.bcp.2026.117976
MLA
Li X, et al.. "Bufalin reverses oxaliplatin resistance in gastric cancer by targeting YBX1 to suppress glycolysis.." Biochemical pharmacology, vol. 250, no. Pt 1, 2026, pp. 117976.
PMID
41991006
Abstract
Oxaliplatin resistance is a key challenge in gastric cancer therapy. This study explored how bufalin, an active component of Chansu, reverses this resistance. We found that bufalin targets the transcription factor YBX1, which is upregulated in resistant cells. YBX1 activates STC1 expression, leading to PI3K/Akt pathway activation, increased HK2 levels, and enhanced glycolysis-all contributing to resistance. Bufalin inhibits this YBX1/STC1/glycolysis axis. Using in vitro assays (proliferation, apoptosis, glycolysis measurement) and in vivo models, we demonstrated that bufalin suppresses glycolysis and restores oxaliplatin sensitivity. Mechanistic studies (RNA-seq, ChIP, SPR, etc.) confirmed the direct YBX1-bufalin interaction. Our work reveals YBX1/STC1-mediated glycolysis as a novel resistance mechanism and identifies bufalin as a promising therapeutic agent to overcome it.
같은 제1저자의 인용 많은 논문 (5)
- Progress of clinical research on fractional laser treatment of androgenetic alopecia: A review article.
- Efficacy and Safety of Botulinum Toxin Type A for Treatment of Glabellar Lines: A Network Meta-Analysis of Randomized Controlled Trials.
- Sunken Upper Eyelid Deformity Correction by Orbital Fat Pad Repositioning and Orbicularis Oculi Muscle Folding in Blepharoplasty.
- Forehead Fat Grafting: Asian Facial Contouring and Augmentation.
- Effects of Virtual Reality-Based Cognitive Behavioral Therapy on Sick Role Adaptation for Patients With Colorectal Cancer: A Randomised Controlled Trial.